PFSA

Profusa, Inc. Common Stock

PFSA

Market cap $13.1M

Overview Fund Activity

0.3999 USD

-0.0101

2.46%

At close Updated Sep 2, 10:21 AM EDT

1 day

-2.46%

5 days

-39.94%

1 month

-32.8%

3 months

-80.2%

6 months

-80.2%

Year to date

-80.2%

1 year

-80.2%

5 years

-80.2%

10 years

-80.2%

About: Profusa Inc is a digital health technology company based in Emeryville, CA, that has developed a real-time, consumer-friendly platform that is designed to measure an individual's biochemistry, be easy to use, be cost-effective, and provide the necessary data to manage chronic disease and health and wellness decisions to improve health outcomes for a large population of potential users. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.

Healthcare Medical Devices

–

Funds holding %

of 7,446 funds

–

Analysts bullish %

Financial journalist opinion

Based on 3 articles about PFSA published over the past 30 days

Profusa Announces Commercial and Clinical Collaboration with Head of Angiography, Medical University of Graz, Austria

Led by Prof. Dr. Marianne Brodmann, PI of clinical studies for the Lumee™ Oxygen CE Mark, collaboration includes practice adoption and platform integration in cases and clinical study programs

Profusa Announces Commercial and Clinical Collaboration with Head of Angiography, Medical University of Graz, Austria

Profusa Welcomes Former Acting U.S. Veterans Affairs Secretary Peter O'Rourke as Lead Independent Director; Adds Seasoned Finance Executive Fred Knechtel as CFO

Board addition served in the Trump Administration, overseeing 1,300 facilities serving more than 9 million veterans; New CFO has led finance and operations at companies including Northrop Grumman, Stanley Black & Decker, and DuPont

Profusa Welcomes Former Acting U.S. Veterans Affairs Secretary Peter O'Rourke as Lead Independent Director; Adds Seasoned Finance Executive Fred Knechtel as CFO

Profusa, Inc. Provides Strategy Overview and Business Update for Investors

BERKELEY, Calif, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (NASDAQ: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, provides a strategy overview and business update from Chairman and CEO, Ben Hwang, Ph.D. in the following Letter to Shareholders:

Profusa, Inc. Provides Strategy Overview and Business Update for Investors

Profusa Secures Lumee™ Oxygen Platform Distributor in Spain

BERKELEY, Calif, July 31, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (NASDAQ: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, announces it has signed a Letter of Intent (LOI) to enter into a distribution agreement in Spain for its Lumee Oxygen platform. The Spanish distributor, Dismeval, S.L., specializes in the distribution of medical and surgical equipment throughout Spain, including the Canary and Balearic Islands. The distribution partner has an experienced and well trained team with in-depth knowledge of the medical device sector and hands-on expertise in supporting hospital-based clinical and technical operations.

Profusa Secures Lumee™ Oxygen Platform Distributor in Spain

Profusa Announces $100 Million Equity Line of Credit to Initiate Bitcoin Treasury Strategy

BERKELEY, Calif, July 21, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (NASDAQ: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, today announced that it is initiating a Bitcoin treasury strategy via the execution of a Securities Purchase Agreement (the “ELOC”) with Ascent Partners Fund LLC, (“Ascent”), pursuant to which Ascent will purchase up to $100,000,000 of the Company's Common Stock. 100% of the net proceeds will be used to purchase Bitcoin (which can be used for debt repayment) provided that the Company's cash balance on the date of the put exceeds $5,000,000.

Profusa Announces $100 Million Equity Line of Credit to Initiate Bitcoin Treasury Strategy

Profusa Announces Closing of Business Combination and the Commencement of Trading on Nasdaq

Profusa's Common Stock is Expected to Begin Trading on Nasdaq on Monday, July 14, 2025 Under the Ticker "PFSA" BERKELEY, Calif, July 11, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, today announced the closing of its business combination with NorthView Acquisition Corp. (“NVAC”), a special purpose acquisition company, which was approved by NVAC's shareholders on June 9, 2025. The combined company will operate under the name Profusa, Inc., with its common stock expected to begin trading on Nasdaq under the ticker symbol “PFSA”, beginning on July 14, 2025.

Profusa Announces Closing of Business Combination and the Commencement of Trading on Nasdaq

See News Rankings

Charts implemented using Lightweight Charts™